Shire
Michael Cola resigns from Shire
April 3, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Michael Cola, Shire
Michael Cola has resigned as the president of Shire Specialty Pharmaceuticals after seven years at the firm. “On behalf of …
Shire signs CNS disorders deal with Heptares
March 23, 2012Research and Development A2A, CNS, GPCR, Heptares, Shire
Shire is to develop and commercialise a novel adenosine A2A antagonist discovered by Heptares currently in pre-clinical development.UK-based Heptares discovers and …
‘Rare Disease Day’ highlights need for research
February 29, 2012Research and Development, Sales and Marketing Genzyme, Rare Disease Day, Shire
Today has been designated as Rare Disease Day around the world, with researchers, regulators and the industry all raising awareness …
Shire signs antibody research deal with arGEN-X
February 29, 2012Research and Development Shire, arGEN-X, monoclonal antibodies
Shire has signed a deal with antibody specialists arGEN-X to develop drugs for rare genetic diseases.Rotterdam-based arGEN-X will use its …
Shire’s Vpriv plant wins EU approval
February 28, 2012Manufacturing and Production EMA, Shire, Vpriv
Shire has been told by the European Medicines Agency that it can make use of a manufacturing facility in Lexington, …
Robust sales for Shire
February 13, 2012Sales and Marketing Replagal, Shire, Vpriv, Vyvanse
A rise in the use of attention deficit and hyperactivity disorder drugs has helped push Shire’s turnover past $4 billion …
Shire signs strategic partnership deal with ICON
January 10, 2012Research and Development ICON, Shire
Contract research organisation ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to be the sole global provider of …
Shire facility could answer rare disease drug shortage
November 27, 2011Manufacturing and Production Fabry disease, Gaucher, Shire, Vpriv
Shire has filed applications with the European and US regulators to produce its Gaucher disease drug Vpriv (velaglucerase alfa) at …
Shire’s Firazyr gains US approval after initial setback
September 1, 2011Sales and Marketing FDA, Firazyr, Shire
After three years of waiting Shire’s Firazyr has been approved by the FDA for sudden attacks of swelling. The US …
Shire sales rocket with 25% growth
July 29, 2011Sales and Marketing ADHD, Fabry disease, Gaucher's disease, Shire
Specialist pharma company Shire has posted exceptionally strong results for the second quarter, increasing its product sales by 30% and …
Shire gets green light for second Replagal facility
June 28, 2011Manufacturing and Production Replagal, Shire, Vpriv, pharma manufacturing news
The European Medicines Agency has approved a second manufacturing facility in the USA for Shire’s Fabry disease treatment Replagal. Shire’s …
Shire promotional magnet attracts FDA wrath
May 20, 2011Medical Communications, Sales and Marketing FDA, Shire
The use of a promotional magnet by marketers at Shire has attracted trouble from the FDA. The magnet, which is …
Shire makes $750m regenerative medicines acquisition
May 18, 2011Manufacturing and Production, Research and Development, Sales and Marketing Shire, regenerative medicine
Shire’s ambitions to build a regenerative medicine business will soon be realised following its $750 million acquisition of Advanced BioHealing. …
Shire thrives on specialist portfolio
February 11, 2011Sales and Marketing 2010 pharma results, ADHD, Shire, Vyvanse
Speciality pharma company Shire has posted sales growth of 16%, led by its ADHD treatment Vyvanse. Sales of Vyvanse rose …
Shire bags senior research execs from GSK and Abbott
February 9, 2011Research and Development Dr Lawson Macartney, Dr Mario Saltarelli, Shire, appointment, recruitment, research and development
Shire has strengthened its speciality pharmaceuticals business with the appointment of senior research executives from GlaxoSmithKline and Abbott. Dr Lawson …
Latest content
